Anavex Life Sciences Corp (AVXL)

[TTTav66]

I do feel uneasy, based on experience, when I see a biotech taking on lots of funding and starting on a new pipeline drug just before an important readout.

I've seen you assert your sense of personal unease with 3-71 moving forward at this point several times now, but since plans were in the works since at least early/mid-2020 to initiate the Phase 1 Anavex 3-71 trial (per corporate presentation catalyst slides), I have a hard time drawing a similar correlation in regards to the timing. Would your expectation have been for the company to run the Phase 1 then hold on communicating any plans for advancement until after all concurrently running blarcamesine trials read out? Genuinely curious...